Kezar Life Sciences Inc Stock

$4.13

0.72%

Nasdaq, Apr 21, 08:46 pm CET

ISIN

US49372L1008

Symbol

KZR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Kezar Life Sciences Inc Stock price

$4.16

-41.34 90.86% 5Y

Nasdaq, Closing price Thu, Apr 17 2025

+0.10 2.46%

ISIN

US49372L1008

Symbol

KZR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$30.39m
Enterprise Value	$-85.68m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	1.15
P/B ratio (TTM) P/B ratio	0.26
Revenue growth (TTM) Revenue growth	-100.00%
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-89.14m
Free Cash Flow (TTM) Free Cash Flow	$-74.24m
Cash position	$132.25m
EPS (TTM) EPS	$-11.49
P/E forward	negative
Short interest	0.84%

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Get Started for Free Today

Kezar Life Sciences Inc Stock Analysis

Unlock Scores for Free

??

5 Analysts have issued a Kezar Life Sciences Inc forecast:

3x Buy

60%

2x Hold

40%

More details on Analyst Estimates Including Price Targets

5 Analysts have issued a Kezar Life Sciences Inc forecast:

Buy

60%

Hold

40%

Analyst Estimates with Stock Price Targets

Financial data from Kezar Life Sciences Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	1.04 1.04	3% 3% -
Gross Profit	-1.04 -1.04	118% 118% -
- Selling and Administrative Expenses	21 21	13% 13% -
- Research and Development Expense	66 66	23% 23% -
EBITDA	-88 -88	15% 15% -
- Depreciation and Amortization	1.04 1.04	3% 3% -
EBIT (Operating Income) EBIT	-89 -89	15% 15% -
Net Profit	-84 -84	18% 18% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Kezar Life Sciences Inc Stock News

Neutral

Seeking Alpha

●

27 days ago

Kezar Life Sciences, Inc. (KZR) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call (Transcript)

Kezar Life Sciences, Inc. (NASDAQ:KZR ) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call March 25, 2025 8:00 AM ET Company Participants Chris Kirk - Chief Executive Officer & Co-Founder Dr. Craig Lammert - Principal Investigator of PORTOLA Study Gideon Hirschfield - Professor University of Toronto, Autoimmune Liver Disease Research Conference Call Participants Matt Phipp...

Neutral

Business Wire

●

27 days ago

Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported positive topline results from the PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a novel, first-in-class selective immunoproteasome inhibitor, in patie...

Neutral

Business Wire

●

28 days ago

Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025

SOUTH SAN FRANCISCO, CALIF.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will present topline results from the PORTOLA Phase 2a trial evaluating zetomipzomib for the treatment of patients with autoimmune hepatitis (AIH) on Tu...

More Kezar Life Sciences Inc News

Company Profile

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco, California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.

Head office	United States
CEO	Christopher Kirk
Employees	55
Founded	2015
Website	www.kezarlifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now